Novartis’ “Captainship” Program Produces More Hypertension Market Share
Executive Summary
Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market
You may also be interested in...
Novartis Forging Ahead: Exforge Gets Full Approval, To Launch By End Of June
Novartis will launch its hypertension treatment Exforge by the end of the month following FDA final approval of the product. The drug is the first to combine an angiotensin receptor blocker, Novartis' Diovan (valsartan), with a calcium channel blocker, Pfizer's Norvasc (amlodipine)
Novartis Forging Ahead: Exforge Gets Full Approval, To Launch By End Of June
Novartis will launch its hypertension treatment Exforge by the end of the month following FDA final approval of the product. The drug is the first to combine an angiotensin receptor blocker, Novartis' Diovan (valsartan), with a calcium channel blocker, Pfizer's Norvasc (amlodipine)
Will Novartis’ Tekturna Be Buoyed By Category Captainship?
The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas